Linzagolix FDA Approval Status
Last updated by Judith Stewart, BPharm on Sep 16, 2021.
FDA Approved: No
Generic name: linzagolix
Company: ObsEva SA
Treatment for: Uterine Fibroids
Linzagolix is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the treatment of women with uterine fibroids.
- Linzagolix is a novel, orally administered GnRH receptor antagonist that potentially provides effective management of heavy menstrual bleeding (HMB) associated with uterine fibroids (UF) while mitigating bone mineral density loss and other adverse effects typically associated with currently approved treatments.
- Linzagolix is also in late-stage clinical development for the treatment of pain associated with endometriosis.
Development Timeline for linzagolix
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.